| abstract |
This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof, wherein Y?1, Y2, Y3, and Y4¿ are independently selected from N, CH, etc.; R1 is H, C¿1-8? alkyl, etc.; Q?1¿ is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is C¿1-6? alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R?2¿ is H, C ¿1-4? alkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, C1-4 alkyl, etc.; m is o,1 or 2; R?3 and R4¿ are independently selected from H and C¿1-4? alkyl; R?5¿ is H, C¿1-4? alkyl, etc.; Q?2¿ is a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc. These compounds are useful for the treatment of medical conditions mediated by prostaglamndin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound. |